Supplementary Information

Dual-Targeting Tumor and Subcellular Endoplasmic Reticulum viaAgPPIX-basedJanusNanoparticlesforPhotodynamic/Immunotherapy of Triple-negative Breast CancerKun Ma ‡*a, He Diao ‡a, Xiangyi Xu a, Yu Jin b, Mingling Qiu b, Zicheng Liu a, ChenboYang a, Jiacheng Zhao a, Senchao Chai a, Qingxian Fang a, Zhaoming Guo a, ChanghaoCui a, Jianqiang Xu a, c, Liangwei Yin *d, Hai-ying Ma *b

^a School of Chemical Engineering, Ocean and Life Sciences, Dalian University of Technology, Panjin 124221, Liaoning Province, China

^b Department of Histology and Embryology, Dalian Medical University, Dalian
116044, Liaoning Province, China

^c Panjin Institute of Industrial Technology, Dalian University of Technology, Panjin 124221, China

^d Department of Oncology, Central Hospital of Dalian University of Technology, Dalian 116033, China

‡These authors contributed equally to this study



Figure S1. EDS result of PAPC.



Figure S2. The preparation of Pickering emulsions. (a) the PDA NPs suspensions; (b) the physical mixture of paraffin and water; (c); the physical mixture of paraffin and PDA NPs suspensions (d) the Pickering emulsions of paraffin and PDA NPs.



Figure S3. SEM image of synthesized NPs. (a) SEM of PA; (b) SEM of PAP; (c) SEM of PAC. Scale bar: 1 μ m.



Figure S4. The histologic section of heart, live, spleen, lung, kidney with H&E staining after treated by saline, PA, PAPC without laser and PAPC with laser. Scale bar: 500 μ m.

Nanomedicine	Without Laser (IC50)	With Laser (IC50)
AgPPIX	56.18 μg/mL	65.38 μg/mL
РА	45.10 μg/mL	37.81 μg/mL
PAP	44.44µg/mL	35.32 μg/mL
PAC	37.79 μg/mL	25.09 μg/mL
PAPC	22.96 µg/mL	16.55 μg/mL

Table. S1. IC50 of AgPPIX, PA, PAP, PAC and PAPC (Without Laser; With Laser).